

24th Symposium on Medicinal Chemistry in Eastern England

Thursday, 25th April 2013
Fielder Centre, Hatfield, Hertfordshire, UK

- 09:30 Registration and refreshments
Chairman: **Prof Simon Ward** (University of Sussex)
- 10:00 Welcome and introduction
- 10:05 Epigenetic modulation of the pro-inflammatory macrophage response -
discovery of a selective Jumonji H3K27 demethylase inhibitor
Robert Sheppard (GlaxoSmithKline)
- 10:45 Discovery of potent and selective Syk inhibitors for the treatment of asthma
Bernat Vidal (Almirall)
- 11:25 Development of acidic molecules as drug candidates: A medicinal chemistry
perspective
Nigel Swain (Pfizer)
- 12:05 Lunch
- Chairman: **Prof Robin Ganellin** (University College London)
- 13:10 GNE-7915: A potent, selective and brain-penetrant LRRK2 inhibitor
Mark Chambers (BioFocus)
- 13:50 Discovery of a novel chemotype of ENaC blockers for the treatment of cystic
fibrosis
Tom Hunt (Novartis)
- 14:30 From virtual to clinical: The discovery of the EP4 receptor antagonist, AP-
1531
David Clark (Argenta)
- 15:10 Refreshments
- 15:30 Structure-based design of irreversible kinase inhibitors
Richard Ward (AstraZeneca)
- 16:10 From PSK1404 to GLPG0187, clinical candidate: How to overcome toxicity in
the integrin receptor antagonist program
Bertrand Heckmann (Galapagos)
- 16:50 Concluding remarks
17:00 Close